Surgical Science Q2: Initial take - Redeye

Redeye provides its initial take on Surgical Science’s Q2 2022 report, which came in above our estimates. We judge that positives from the report include strong sales growth in both business segments and EBITDA/EBIT margins considerably exceeding our Q2 estimates.

Länk till analysen i sin helhet: https://www.redeye.se/research/853216/surgical-science-q2-2022-initial-take?utm_source=finwire&utm_medium=RSS